<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD011385-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD011385-sec1-0001"></div> <div class="table" id="CD011385-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Summary of findings table</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="left" valign="top" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>Antifibrinolytic therapy compared with placebo or usual care for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing oral or dental procedures</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population</b>: people with haemophilia or Von Willebrand disease </p> <p><b>Settings</b>: hospitals, hemophilia centres </p> <p><b>Intervention:</b> tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) </p> <p><b>Comparison</b>: placebo or no intervention or usual care with or without placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects<sup>*</sup></b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>â of participants<br> (studies)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="2" class="table-header"> <p><b>Number needed to treat (NNT)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo or usual care</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with antifibrinolytic therapy</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Postoperative bleedings requiring intervention</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>Study population</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Risk difference:</p> <p>57<br> (36 to 76) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>59<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>1.8</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> MODERATE <sup>1 2 3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"></td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>67 per 100</p> <p>(20 events)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>10 per 100</p> <p>(3 events)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Side effects or other adverse events</p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p>Study population</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Risk difference:</p> <p>3.4<br> (â32 to 38) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>59<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>0.3</p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ââââ<br> LOW <sup>2 3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"></td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>0 events</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>1 event</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="8" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><br><b>CI</b>: confidence interval; <b>RR</b>: risk ratio; <b>OR</b>: odds ratio; </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="8" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality</b>: we are very confident that the true effect lies close to that of the estimate of the effect<br><b>Moderate quality</b>: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br><b>Low quality</b>: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br><b>Very low quality</b>: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> The magnitude of effect was considered large in this study, therefore the quality of evidence was rated up one level. </p> <p><sup>2</sup> Small sample sizes and lack of studies </p> <p><sup>3</sup> Heterogeneity between the included trials regarding the proportion of severe people with haemophilia included, the concomitant standard therapy and fibrinolytic agent treatment regimens used </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
